Aquestive Therapeutics (AQST) Other Operating Expenses (2017 - 2026)

Aquestive Therapeutics' Other Operating Expenses history runs 10 years deep, the most recent figure standing at $3.5 million for Q1 2026.

• On a quarterly basis, Other Operating Expenses fell 5.01% year-over-year to $3.5 million in Q1 2026; TTM through Mar 2026 was $18.4 million, a 7.22% increase from a year earlier, with the FY2025 full-year figure at $18.6 million, up 3.82% from the prior year.
• Other Operating Expenses slipped to $3.5 million in Q1 2026 per AQST's latest filing, from $5.8 million in the prior quarter.
• Across five years, Other Operating Expenses topped out at $6.6 million in Q2 2023 and bottomed at $3.5 million in Q1 2026.
• The 5-year median for Other Operating Expenses is $4.6 million (2025), against an average of $4.7 million.
• Across the five-year window, Other Operating Expenses jumped 57.61% in 2022 and tumbled 31.6% in 2024, its largest moves.
• Year by year, Other Operating Expenses stood at $5.3 million in 2022, then declined by 11.8% to $4.7 million in 2023, then decreased by 3.4% to $4.5 million in 2024, then increased by 29.12% to $5.8 million in 2025, then tumbled by 40.56% to $3.5 million in 2026.
• Per Business Quant, the three latest AQST Other Operating Expenses figures stand at $3.5 million (Q1 2026), $5.8 million (Q4 2025), and $4.5 million (Q3 2025).